Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Michael S., Nemunaitis, John, Barve, Minal, Wainberg, Zev A., Hamilton, Erika P., Ramanathan, Ramesh K., Sledge, George W., Yue, Huibin, Morgan-Lappe, Susan E., Blaney, Martha, Kasichayanula, Sreeneeranj, Motwani, Monica, Wang, Lan, Naumovski, Louie, Strickler, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398147/
https://www.ncbi.nlm.nih.gov/pubmed/34315767
http://dx.doi.org/10.1158/1535-7163.MCT-20-0985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398147/
https://www.ncbi.nlm.nih.gov/pubmed/34315767
http://dx.doi.org/10.1158/1535-7163.MCT-20-0985

Ejemplares similares